Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
Stock Market Today: Dow Tumbles 450 Points As Yields Jump; Fed Minutes On Deck (Live Coverage)
07.10.2026 14:23
The Dow Jones index drops 450 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.
Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163
07.10.2026 10:34
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.
Gilead Sciences signs five-year DevOps agreement with Cognizant
07.10.2026 08:21
The arrangement will see Cognizant combine its life sciences knowledge with technical services to aid Gilead's processes.
Gilead Sciences (NASDAQ:GILD) Offers Dividend Investors Quality Income and Valuation Support
05.10.2026 11:20
Gilead Sciences (GILD) passes a high-quality dividend screen with a 3.98% yield, strong profitability, cheap valuation, and key risks to watch.
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
05.10.2026 11:00
Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend th
Nurix Gets $10M As Gilead Extends Drug Discovery Deal
05.10.2026 07:10
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and
Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup
02.10.2026 10:11
Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
02.10.2026 02:25
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
01.10.2026 12:00
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
30.09.2026 08:47
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
30.09.2026 05:26
Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline isn’t a transition plan” and lives could be at risk.
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?
28.09.2026 13:11
Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
22.09.2026 09:49
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
20.09.2026 04:17
Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The PAHO partnership creates a direct pathway for 14 additional countries in the region to obtain lenacapavir for HIV prevention programs. Gilead's broader licensing...
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
18.09.2026 16:51
Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]
4 Biotech Stocks to Watch as Potential Takeover Targets
18.09.2026 16:31
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
15.09.2026 13:11
Gilead Sciences, Inc. (GILD) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:45 AM EDTCompany ParticipantsDaniel O'Day -...
Gilead Sciences Inc's Dividend Analysis
15.09.2026 11:01
This article first appeared on GuruFocus. Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15. This upcoming distribution includes a $0.82 per share cash dividend payable on 2026-09-29.
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
10.09.2026 04:02
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat